Cost-effectiveness and budget impact analyses for the prioritisation of the four available rotavirus vaccines in the national immunisation programme in Thailand

Rotavirus is a major cause of diarrhoea in children less than five years old Thailand. Vaccination has been shown to be an effective intervention prevent rotavirus infections but yet enlisted the national immunisation programme. This study aimed assess cost-utility introducing vaccines, taking all WHO-prequalified vaccines into consideration. A analysis was performed using transmission dynamic model estimate, from societal perspective, costs and outcomes four vaccines: Rotarix®, RotaTeq®, ROTAVAC® ROTASIIL®. The used simulate impact among aged < 1 year compare this with no vaccination. vaccination programme considered cost-effective if incremental cost-effectiveness ratio threshold USD 5,110 per QALY gained. Overall, without vaccine, predicted average annual incidence 312,118 cases. With at coverage more 95%, number cases averted estimated 144,299 year. All were cost-saving. ROTASIIL® most cost-saving option, followed by ROTAVAC®, Rotarix® providing cost-savings 32, 31, 23 22 million year, respectively, 999 QALYs remained lower gained, even when ignoring indirect beneficial effects. net saving healthcare system implementing any one these would between 13 33 should included Implementing reduce government spending while yielding health benefits population.